Dengue virus causes approximately 96 million symptomatic infections annually,manifesting as dengue fever or occasionally as severe dengue1,2.There are no antiviral agents available to prevent or treat dengue.Here,we d...Dengue virus causes approximately 96 million symptomatic infections annually,manifesting as dengue fever or occasionally as severe dengue1,2.There are no antiviral agents available to prevent or treat dengue.Here,we describe a highly potent dengue virus inhibitor(JNJ-A07)that exerts nanomolar to picomolar activity against a panel of 21 clinical isolates that represent the natural genetic diversity of known genotypes and serotypes.The molecule has a high barrier to resistance and prevents the formation of the viral replication complex by blocking the interaction between two viral proteins(NS3 and NS4B),thus revealing a previously undescribed mechanism of antiviral action.展开更多
文摘Dengue virus causes approximately 96 million symptomatic infections annually,manifesting as dengue fever or occasionally as severe dengue1,2.There are no antiviral agents available to prevent or treat dengue.Here,we describe a highly potent dengue virus inhibitor(JNJ-A07)that exerts nanomolar to picomolar activity against a panel of 21 clinical isolates that represent the natural genetic diversity of known genotypes and serotypes.The molecule has a high barrier to resistance and prevents the formation of the viral replication complex by blocking the interaction between two viral proteins(NS3 and NS4B),thus revealing a previously undescribed mechanism of antiviral action.
